Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
Cytomegalovirus (CMV)-specific immune reconstitution early after stem cell transplantation (SCT) was evaluated prospectively by detecting CD8+ T-cells, which recognize the peptide QYDPVAALF in the context of HLA-A*2402. Fifteen allogeneic SCT recipients were included in the study. All recipients and donors were seropositive for CMV and had the HLA-A*2402 allele. CMV-specific T-cells were detected as early as 1 month after transplantation, and their numbers increased to peak levels 2 to 5 months after transplantation. The numbers of CMV-specific T-cells in patients who developed grade II to IV acute graft-versus-host disease (GVHD) and received corticosteroids for acute GVHD were low in the early period after allogeneic SCT. There was a trend toward earlier reconstitution of CMV-specific CD8+ T-cells in allogeneic peripheral blood SCT (PBSCT) patients than in allogeneic bone marrow transplantation patients. The contribution of T-cells in the graft to the recovery of CMV-specific immune responses was also suggested by the finding that the reconstitution of CMV-specific CD8+ T-cells was delayed in CD34-selected autologous PBSCT compared with unpurged autologous PBSCT. The reconstitution of CMV-specific CD8+ T-cells was delayed in patients with CMV disease or recurrent CMV reactivation. These observations suggest that the detection of CMV-specific T-cells with an HLA-peptide tetramer is useful to assess immune reconstitution against CMV and to identify patients at risk for CMV disease or recurrent CMV reactivation after SCT.
Gondo
Hisashi
H
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan. gondo@hamanomachi.jp
Himeji
Daisuke
D
Kamezaki
Kenjiro
K
Numata
Akihiko
A
Tanimoto
Tetsuya
T
Takase
Ken
K
Aoki
Kenichi
K
Henzan
Hideho
H
Nagafuji
Koji
K
Miyamoto
Toshihiro
T
Ishikawa
Fumihiko
F
Shimoda
Kazuya
K
Inaba
Shuichi
S
Tsukamoto
Hiroshi
H
Horiuchi
Takahiko
T
Nakashima
Hitoshi
H
Otsuka
Takeshi
T
Kato
Koji
K
Kuroiwa
Mika
M
Higuchi
Masakazu
M
Shibuya
Tsunefumi
T
Kamimura
Tomohiko
T
Kuzushima
Kiyotaka
K
Tsurumi
Tatsuya
T
Kanda
Yoshinobu
Y
Harada
Mine
M
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D049109:Cell Proliferation; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology*; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000276:immunology; D015234:HLA-A Antigens / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007945:Leukemia, Lymphoid / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000276:immunology*; D014184:Transplantation, Homologous
D000305:Adrenal Cortex Hormones; D018952:Antigens, CD34; D015234:HLA-A Antigens; D009842:Oligopeptides